Vaxxinity (OTCMKTS:VAXX – Get Free Report) is projected to post its resultson Wednesday, August 12th. Analysts expect Vaxxinity to announce earnings of ($0.12) per share for the quarter.
Vaxxinity Price Performance
Shares of OTCMKTS VAXX opened at $0.00 on Wednesday. The firm has a market capitalization of $12,675.00, a price-to-earnings ratio of -0.00 and a beta of -74.53. Vaxxinity has a one year low of $0.00 and a one year high of $0.20. The company has a fifty day moving average price of $0.01.
Vaxxinity Company Profile
Vaxxinity, Inc (NASDAQ: VAXX) is a clinical-stage biotechnology company focused on the development of peptide-based vaccines for serious diseases. Leveraging its proprietary synthetic peptide vaccine platform, the company designs antigens that co-present B-cell and T-cell epitopes to elicit robust and durable immune responses. Vaxxinity’s manufacturing collaborations support clinical-scale production and aim to facilitate broader commercial supply.
The company’s lead clinical programs include UB-311, an active immunotherapeutic vaccine candidate for Alzheimer’s disease currently in mid-stage trials, and UB-612, a multitope vaccine candidate for SARS-CoV-2 intended as a next-generation COVID-19 booster.
Further Reading
- Five stocks we like better than Vaxxinity
- Palantir Soars 30% After Blockbuster Earnings—Is the Rally Just Getting Started?
- Visa’s BioCatch Deal Could Make Fraud Prevention a Bigger Business
- Caterpillar’s Record Quarter May Have Reset the Stock’s Ceiling
- The Real Reason Amazon Hit a $3 Trillion Valuation
Receive News & Ratings for Vaxxinity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxxinity and related companies with MarketBeat.com's FREE daily email newsletter.
